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As the number of genes identified for linkage to hearing loss has been increasing and more public 
databases have become available, we aimed to systematically evaluate all variants reported for 
nonsyndromic hearing loss (NSHL) based on their allele frequencies (AFs) in the general population. 
Among the 3,549 variants in 97 NSHL genes reported as pathogenic/likely pathogenic in ClinVar and 
HGMD, 1,618 were found in public databases (gnomAD, ExAC, EVS, and 1000G). To evaluate the 
pathogenicity of these variants, we employed AF thresholds and NSHL-optimized ACMG guidelines. AF 
thresholds were determined using a high-resolution variant frequency framework and Hardy-Weinberg 
equilibrium calculation: 0.6% and 0.1% for recessive and dominant genes, respectively. Filtering AFs of 
variants linked to NSHL were obtained based on AFs reported in gnomAD and ExAC. We found that 48 
variants in 23 genes had filtering AFs above the suggested thresholds and assumed that these variants 
might be benign based on their filtering AFs. 47 variants, except for one notorious high-frequency GJB2 
mutation (c.109G > A; p.Val37Ile), were confirmed to be benign/likely benign by the NSHL-optimized 
ACMG guidelines. The proposed systematic approach will aid in precise evaluation of NSHL variant 
pathogenicity in the context of filtering AFs, AF thresholds, and NSHL-specific ACMG guidelines, thus 
improving NSHL diagnostics.
Rapid advancements in sequencing technologies and bioinformatic tools for genomic data analysis have enabled 
clinicians and researchers to take a step forward in the implementation of precision medicine for Mendelian 
disorders. Large population databases and publicly accessible repositories of disease-causing mutations facilitate 
clinical interpretation of gene variants identified by next-generation sequencing (NGS) in individuals with genetic 
disorders1. In addition, functional assessment of variants both in vitro and in vivo is important for determining 
their contribution to disease pathogenesis. Clinical application of NGS made it possible to identify diagnostic and 
prognostic signatures in a number of diseases, including hereditary hearing loss, whose genetic landscape has 
been actively explored from both diagnostic and therapeutic aspects.
Hearing loss is the most common sensory disorder that affects approximately one in every 500 newborns 
worldwide2. Over two-thirds of hereditary hearing loss cases are diagnosed as nonsyndromic hearing loss 
(NSHL), in which the hearing loss phenotype is the only feature observed without additional symptoms3. Since 
2015, application of NGS technology to discovering novel genetic causes of NSHL enabled identification of 16 
additional genes, whose variants have been linked to NSHL development, and currently, approximately a hundred 
genes are implicated in the disease. However, genetic heterogeneity and phenotypic variability of NSHL makes 
precise interpretation of variants identified by NGS a challenge. Furthermore, it is technically difficult to examine 
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the pathogenic impact of some gene variants associated with NSHL, such as those of MYO15A and CDH23, 
because of very large gene sizes and the absence of relevant functional tests in vitro.
To improve the clinical utility of NGS in NSHL, one useful approach is to consider the allele frequency 
(AF) of a gene variant. Large reference datasets such as Exome Aggregation Consortium (ExAC) and Genome 
Aggregation Database (gnomAD) not only provide high-resolution variant frequencies, but also allow filtering 
AFs with robust statistical significance4. In addition, disease-specific application of optimized American College 
of Medical Genetics (ACMG) guidelines has been attempted for various genetic disorders based on the impor-
tance of pathomechanistic diversity5. Furthermore, widespread availability of mutation databases such as ClinVar 
and Human Gene Mutation Database (HGMD) encouraged researchers to refine strategies for gene variant inter-
pretation and even to reassess outdated mutations reported before the advent of high-precision genetic tools and 
large-scale databases6–8.
In this study, we aimed to systemically evaluate publicly reported genetic variants associated with NSHL in 
terms of their pathogenicity by applying thresholds of AFs newly calculated for the general population. The new 
classification results were validated using the NSHL-specific ACMG guidelines and compared with previous 
reports.
Methods
Systematic collection of pathogenic variants for curated NSHL genes. We comprehensively eval-
uated the evidential level of cause-and-effect relationship for the genes associated with NSHL and created a final 
list of 97 causative genes that were reported in all three examined databases: the Hereditary Hearing Loss (http://
hereditaryhearingloss.org/), Deafness Variation Database (http://deafnessvariationdatabase.org/), and Online 
Mendelian Inheritance in Man (OMIM) database. Furthermore, we selected genes that have enough evidence of 
association with NSHL, such as those with evidential level 2–3 according to previous studies9–11 and with more 
than three clinical reports of hearing loss patients carrying gene variants (Supplementary Table S1). Next, we 
selected all reported gene variants classified as presumably pathogenic in HGMD Professional (accessed May, 
2017) or ClinVar (20170501.ver) databases; variants annotated as “DM” or “DM?” in HGMD or as “pathogenic” 
or “likely pathogenic” in ClinVar were compiled. The annotation and nomenclature of the variants were con-
firmed using the Mutalyzer Name Checker tool based on clinically relevant transcripts in each gene.
General population datasets. To maximize the volume of general population data, we utilized four widely 
used control databases: (1) gnomAD (n = 141,456, http://gnomad.broadinstitute.org/), (2) ExAC (n = 60,706, 
http://exac.broadinstitute.org/), (3) NHLBI Exome Sequencing Project (n = 6,503, http://evs.gs.washington.edu/
EVS/), and (4) 1000 Genomes Project Phase 3 database (1000 G; n = 2,504, http://www.internationalgenome.
org/). We used ‘observed AFs’ representing the count ratio of the actually detected minor alleles to reliably 
sequenced alleles. All reportedly pathogenic or likely pathogenic variants of the 97 NSHL-linked genes were 
searched for observed AF separately in the four databases, which have distinct demographic composition in terms 
of ethnicity and population size. All gnomAD and ExAC data were checked using the “pass” filter to include only 
variants with appropriate coverage.
Determination of AF thresholds. As the AF of a variant in the general population is an essential criterion 
for pathogenicity interpretation, various approaches were used to define the AF threshold at which a variant could 
be interpreted as too common to be classified as “definitely pathogenic”. Since AF thresholds might be fairly differ-
ent depending on disease nature, we applied empirical approaches as well as theoretical calculations to determine 
appropriate AF thresholds for NSHL variants.
First, empirical bottom-up analysis using AF thresholds of 0.005%, 0.01%, 0.05%, and 0.1% was adopted from 
a previous study12 to evaluate overall AF distributions of NSHL-linked gene variants reported to be pathogenic 
in HGMD or ClinVar. As different AF thresholds are used in different studies, we chose the 0.05% threshold sug-
gested in a previous report13 and, in addition, applied two-fold threshold values.
Second, theoretical calculations were performed to obtain evidence-based AF thresholds. Different approaches 
were utilized depending on the mode of inheritance. For dominant genes, the AF cut-off value was obtained using 
the Hardy-Weinberg equilibrium based on the prevalence of hereditary NSHL, since no single mutation was 
reported to represent the majority of dominant NSHL. For recessive genes, we applied the high-resolution variant 
frequency framework suggested by Whiffin et al.14.
Calculation of filtering AF using the gnomAD and ExAC datasets. Filtering AF was previously 
defined as the threshold disease-specific “maximum credible AF” at or below which the disease could not plausi-
bly be caused by that variant14. Filtering AFs were computed using the “inverse AF” calculator of a web-based tool 
(http://cardiodb.org/allelefrequencyapp/). We calculated filtering AFs using observed AFs across all ethnicities in 
the gnomAD and ExAC datasets rather than AFs for sub-populations.
ACMG guideline application and NSHL-specific rules. To systematically evaluate the pathogenic 
potential of presumably pathogenic variants with AFs higher than the thresholds defined for the general popu-
lation, we applied the 2015 ACMG guidelines for variant classification with InterVar, one of the most commonly 
used bioinformatics tools for clinical interpretation of genetic variants15. To enhance the accuracy of analysis, 
we optimized the ACMG guidelines for NSHL based on updates of the NSHL genetic background during the 
last decade. Detailed parameterization of each ACMG guideline components optimized for NSHL is explained 
in Supplementary Notes. Briefly, filtering AF was used for analysis of a population database; in addition, the pLI 
score defined as the probability of a gene being intolerant to a loss-of-function (LoF) mutation9 and guidelines for 
LoF prediction16 were used to determine LoF gene variants linked to NSHL pathophysiology. Results of reliable 
functional studies on hearing loss were manually curated on the evidential basis.
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Comparison of in-silico prediction results between rare and common missense variants accord-
ing to filtering AF. To analyze the association of missense mutations with the scarcity of variants and 
mode of inheritance, we applied three most widely used algorithms: PolyPhen-2 (PP2), Sorting Intolerant from 
Tolerant (SIFT), and Consensus deleteriousness of non-synonymous single nucleotide variants (Condel)17–19. The 
Mann-Whitney test was used to evaluate statistical significance of differences between common and rare variants, 
and a P value less than 0.05 was considered significant.
Results
NSHL-related variants pooled from publicly available databases. For the 97 NSHL causative genes 
curated from three databases (Hereditary Hearing Loss, Deafness Variation Database, and OMIM), a total of 
3,549 variants were reported as presumably pathogenic either in the HGMD or ClinVar. Among them, 1,618 
(45.6%) were present in at least one of four control datasets: gnomAD, ExAC, EVS, and 1000G (Fig. 1).
AF threshold values determined by two approaches. Bottom-up analysis. An empirical approach 
using different AF threshold values (0.005%, 0.01%, 0.05%, and 0.1%) to examine the rarity of a variant in large 
population datasets revealed that 1,598 out of 3,549 (45.0%) variants were reported in gnomAD, whereas only 367 
(10.3%) variants were in 1000G (Supplementary Table S2), demonstrating the higher resolution from more num-
ber of sequenced individuals. In addition, 1,110 (31.3%) and 733 (20.7%) variants with AFs of 0 < AF < 0.005% 
were present in gnomAD and ExAC, respectively, showing the power of sample size (141,456 in gnomAD vs. 
60,706 in ExAC) (Supplementary Table S2). Furthermore, no variant had AF of 0 < AF < 0.005% based on EVS or 
1000G; however, this was due to small sample sizes of EVS or 1000G (Supplementary Table S2). Nevertheless, the 
numbers of variants with AF of less than 0.005% were similar regardless of databases (Supplementary Table S2).
Figure 1. Overall workflow of the study. (a) Deafness variants reported in public mutation databases. The 
number of variants deposited in the Human Gene Mutation Database (HGMD) and ClinVar were 3,082 and 
1,210, respectively. Variants reported as likely pathogenic or pathogenic in HGMD or ClinVar were further 
examined. Among the 3,549 variants, 1,618 were reported in gnomAD, ExAC, EVS, and 1000 G control datasets. 
(b) Variant classification according to allele frequency (AF). Bottom-up analysis, theoretical calculation and 
filtering AF were applied. (c) Evaluation of variant pathogenicity. Variants were interpreted according to the 
NSHL-optimized ACMG guidelines. VUS, variants of unknown significance.
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Theoretical calculations using the Hardy-Weinberg equilibrium and maximum credible AF. For dominant genes, 
the AF threshold of 0.1% was obtained through Hardy-Weinberg equilibrium (see Supplementary Notes)20. For 
recessive genes, the AF threshold was determined using a theoretical formula proposed by Whiffin et al.20, which 
considers reliable estimates for NSHL prevalence, penetrance, and allelic contribution. Using the GJB2 variant 
(c.35delG; p.Gly12Valfs*2), which is the most prevalent recessive mutation according to Sloan-Heggen et al.21, 
the AF threshold was determined as:
√(0.002 × 0.8 × 0.7) × 0.3789 × √(0.2159 × 1) = 0.6% (see Supplementary Notes).
Reclassification of previously reported pathogenic NSHL variants using observed and filtering 
AFs. To examine the validity of AF thresholds derived from theoretical calculations, we investigated the dis-
tribution of variants according to their observed AFs as well as filtering AFs. For dominant genes, 12 variants in 
5 genes showed observed AFs over our threshold of 0.1%. However, when filtering AFs of these 12 variants were 
applied for reassessment, only 6 (50%) remained as common variants with AFs over 0.1% (Fig. 2a). For recessive 
genes, 45 variants in 17 genes presented observed AFs over 0.6%; however, 28.9% (13/45) of them were reclassi-
fied to the category of rare variants with filtering AFs lower than the threshold (0.6%) (Fig. 2b). For genes which 
exhibit both dominant and recessive patterns, 41.2% (7/17) of variants with observed AFs over 0.6% were classi-
fied as rare based on filtering AFs lower than 0.6% (Fig. 2c).
Evaluation of pathogenicity of reclassified NSHL variants using the ACMG guidelines and 
NSHL-specific rules. We applied the NSHL-specific ACMG guidelines to evaluate pathogenicity of variants 
previously considered as common and reclassified as rare using filtering AF and our thresholds (Table 1). Among 
a total of 26 variants in 15 genes that fulfilled the “PM2” component (i.e., absent from controls or observed 
at an extremely low frequency if recessive) for a sufficiently low filtering AF under our thresholds, two vari-
ants had already been classified as pathogenic even without the addition of the “PM2” component. The num-
bers of individuals with homozygous variants in the gnomAD database ranged from 0 to 36 and recessive genes 
had more numbers of homozygotes than dominant genes (Table 1). When we also applied recently released the 
Expert Specified ACMG guidelines for genetic hearing loss developed by ClinGen Working Group13 and updated 
Deafness Variation Database (DVD v8.2)22, the data presented high concordance with our results for all the 
variants (Table 1). On the other hand, almost all of the 48 variants (except for GJB2 c.109G > A; p.Val37Ile), 
which had both observed and filtering AFs higher than the thresholds, were classified as benign or likely benign 
(Supplementary Table S3).
In-silico prediction analysis of NSHL variants according to AF. In addition, we reviewed the in-silico 
prediction results for our missense variants based on AFs and gene-specific features. The predicted scores for 245 
missense mutations in dominant genes did not show statistically significant differences between variants with 
AFs below and above the threshold. However, the prediction scores of 1,047 and 668 missense mutations for 
recessive genes and genes with both inheritance modes, respectively, calculated by three algorithms (PP2, SIFT, 
and Condel) were statistically different between common and rare variants, i.e., those with AFs above and below 
the thresholds, respectively (Supplementary Fig. S1).
Furthermore, we performed pathogenicity evaluation of 1,960 missense variants according to filtering AFs 
and InterVar prediction. When an agreement was reached among the three in-silico algorithms in the prediction 
results, the variants were classified as neutral (all concordant benign results by three algorithms) or deleterious 
(all concordant damaging results by three algorithms), otherwise mixed (Fig. 3). Interestingly, only pathogenic 
variants were identified in the rare variant groups with AFs below the thresholds regardless of the prediction 
consensus among the three algorithms. Although the proportion of pathogenic variants was the highest in the 
deleterious group (24%), the presence of pathogenic mutations in the neutral and mixed groups was still notice-
able (9% in both, respectively).
Discussion
We systematically evaluated all the reported NSHL-linked pathogenic variants available in population data-
bases by applying clinically plausible AF thresholds, gnomAD and ExAC filtering AF, and NSHL-optimized 
ACMG guidelines. It should be reassuring for clinicians that over 85% of all presumably pathogenic variants 
were ultra-rare with observed AFs below 0.05% in bottom-up analysis. However, application of the gnomAD 
and ExAC filtering AF to 74 reported variants with unexpectedly high observed AFs (i.e., over our AF thresh-
olds) allowed us to safely consider 47 variants with still high filtering AFs as not likely NSHL-related, with the 
notorious exception of one variant (GJB2 c.109G > A; p.Val37Ile)23. Two pathogenic variants identified by the 
NSHL-specific ACMG guidelines were among those reclassified from “common” to “rare” by application of the 
filtering AF, suggesting high clinical utility and accuracy of the AF thresholds determined in this study: 0.1% for 
dominant genes and 0.6% for recessive genes. In other words, we validated the utility of AF cut-off values using 
large-scale datasets in the interpretation of NSHL gene variants with undefined rarity.
Several well-designed studies for NSHL variant interpretation have been previously performed. In 2014, 
Shearer et al.20 were the first to determine ethnicity-specific AF thresholds for NSHL-linked gene variants based 
on several population datasets, including EVS and 1000 G. They provided Deafness Variation Database, which is 
an invaluable resource for researchers and clinicians in the deafness field. However, gnomAD, which comprises 
more than several million variants and is considered the largest database of human variations, was launched in 
2017. Therefore, in this study we combined the recently developed high-resolution framework with the updates 
in population and mutation datasets, and in the NSHL genetic basis to validate gene variants related to NSHL 
etiology. As a result, we found that previously suggested AF thresholds (0.05% and 0.5% for autosomal dominant 
and autosomal recessive genes, respectively), although being fairly satisfactory, were too stringent compared to 
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our thresholds for considering a variant as pathogenic based only on its rarity in population databases. Thus, 
in Deafness Variation Database, Shearer et al.20 reported exceptions for alleles of four genes: GJB2, SLC26A4, 
PCDH15, and MYO15A, whereas according to our approach, the only exception is one GJB2 variant.
Figure 2. Comparison of observed and gnomAD filtering allele frequencies (AFs) for variants with observed 
AFs higher than AF thresholds. (a) Twelve variants in 5 dominant genes presented observed AFs over 0.1%; 
among them, 6 variants were reclassified as rare with filtering AFs lower than 0.1% (red vertical dashed line). 
(b) Forty five variants in 17 recessive genes presented observed AFs over 0.6%; among them, 13 variants 
were reclassified as rare with filtering AFs lower than 0.6% (red vertical dashed line in the magnified plot). In 
particular, one nonsense variant of the MYO15A gene (c.5925G > A, p.Trp1975*; red bolded variant), which 
was reclassified as rare based on filtering AF, was classified as pathogenic according to ACMG guideline 
interpretation. Among 45 variants, 23 variants with both observed and filtering AFs lower than 2.0% are 
magnified in the subset for clarity. (c) Seventeen variants in 4 dominant/recessive genes presented observed 
AF over 0.6%; among them, 7 variants were reclassified as rare with filtering AFs lower than 0.6% (red vertical 
dashed line). In particular, one frameshift variant of the GJB2 gene (c.35delG, p.Gly12Valfs*2; red bolded 
variant), which was reclassified as rare variant based on filtering AF, was classified as pathogenic according to 
ACMG guideline interpretation.
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Various studies have claimed discovery of deafness-causing genes; therefore, understanding of gene-specific 
characteristics is important for the interpretation of gene variants associated with NSHL. Tayoun et al.9 have pro-
vided evidence-based approach for analysis of gene-disease associations and their clinical value in hearing loss, 
and similar algorithms in gene curation for different NSHL aspects should be incorporated in future studies and 
applied to a rapidly growing gene list. In this study, we adopted several strategies for optimization of the ACMG 
guidelines for hearing loss; similar attempts toward ACMG guideline refinement have recently been made in var-
ious diseases24–26. Thus, we incorporated reliable gene evaluation results such as identification of LoF genes and 
intragenic regions based on gene tolerance to different mutations into the NSHL-optimized ACMG guidelines27. 
Although some researchers prefer uniform application of ACMG guidelines for simplicity and convenience28, 
we believe that our NSHL-specific ACMG guidelines would enhance the efficiency of assessing the pathogenic 
potential of a gene variant through prompt adaptation of high-quality data by professional curation.
In response to the urgent need for optimization of NSHL variant interpretation, a large panel of experts called 
ClinGen Hearing Loss Working Group has released their opinion on specification of the ACMG guidelines for 
genetic hearing loss13. Upgraded clarification of original ACMG principles enabled ClinGen Working Group to 
provide meticulous modifications for hearing loss variants; however, they applied this specified guideline to small 
number of variants (51 variants in 9 genes). We analyzed NSHL-associated variants reported so far and presented 
the results of systematic assessments, emphasizing the importance of NSHL-specific interpretation approaches 
for genetic diagnosis.
Gene 
Symbol
Nucleotide 
Change
Amino acid 
Change dbSNP
Observed 
AF (%)
Contributing 
Dataset
Filtering 
AF (%, 
gnomAD)
Filtering AF 
(%, ExAC)
Homozygote 
in gnomAD HGMD ClinVar
NSHL-
optimized 
ACMG class
Expert specified 
ACMG class by 
ClinGen13
DVD 
classifi-
cation
DOMINANT GENES (AF threshold: 0.1%)
WFS1 c.353A > C p.Asp118Ala rs71524349 0.3195 1000G 0.0726 0.0892 0 DM LB VUS Likely benign* Benign
WFS1 c.482G > A p.Arg161Gln rs115346085 0.4193 1000G 0.0905 0.0820 2 DM? — Likely benign Likely benign* Benign
WFS1 c.1235 T > C p.Val412Ala rs144951440 0.1398 1000G 0.0600 0.0723 1 DM LB Likely benign Likely benign* Benign
WFS1 c.2195G > A p.Arg732His rs149013740 0.1398 1000G 0.0251 0.0278 0 — VUS|LP VUS Likely benign* Benign
WFS1 c.2209G > A p.Glu737Lys rs147834269 0.2596 1000G 0.0592 0.0782 3 DM LB Likely benign Likely benign* Benign
DIAPH1 c.2032C > T p.Pro678Ser rs186370335 0.1166 ExAC 0.0586 0.0773 0 DM? LB Likely benign Likely benign* Benign
RECESSIVE GENES (AF threshold: 0.6%)
SLC26A4 c.17G > T p.Gly6Val rs111033423 0.9800 ExAC 0.1964 0.8686 6 DM? B|LB Benign Likely benign** Benign
SLC26A4 c.970A > T p.Asn324Tyr rs36039758 1.1382 1000G 0.3040 0.2850 10 DM? B|LB Benign Likely benign** Benign
SLC26A4 c.1363A > T p.Ile455Phe rs375576481 0.7588 1000G 0.3361 0.4050 22 DM? B Benign Likely benign** Benign
SLC26A4 c.2218G > A p.Gly740Ser rs17154353 1.7100 ESP 0.4678 0.4070 29 DM? B|LB Likely benign Benign Benign
MYO3A c.4462A >G p.Lys1488Glu rs34204285 0.9185 1000G 0.3590 0.3530 15 DM VUS|B Likely benign Likely benign* Benign
PCDH15 c.4039C > A p.Gln1347Lys rs61731387 0.8187 1000G 0.2066 0.2054 8 DM? — Likely benign Likely benign* Benign
CDH23 c.1423G > A p.Val475Met rs62622410 1.4377 1000G 0.3967 0.3530 25 DM? — Likely benign Likely benign** Benign
USH1C c.388G > A p.Val130Ile rs55843567 1.5093 ESP 0.4109 0.3780 23 DM? VUS|B Likely benign Likely benign* Benign
MYO15A c.3026C > A p.Pro1009His rs117612144 0.6245 ExAC 0.5727 0.5872 27 DM B Likely benign Benign* Benign
MYO15A c.5925G > A p.Trp1975Ter rs375290498 0.6142 ExAC 0.1528 0.5311 2 DM VUS|P Pathogenic Likely Pathogenic*
Likely 
pathogenic
MYO15A c.6796G > A p.Val2266Met rs114274755 0.9984 1000G 0.4541 0.7514 5 DM? B|LB Likely benign Likely benign* Benign
MYO15A c.10573A >G p.Ser3525Gly rs182332665 1.2579 1000G 0.5530 0.6025 35 DM? B Likely benign Likely benign* Benign
TRIOBP c.6736G > A p.Glu2246Lys rs138139146 0.6120 ExAC 0.4966 0.5700 3 DM — Likely benign Benign* Benign
DOMINANT/RECESSIVE GENES (AF threshold: 0.6%)
GJB3 c.529T >G p.Tyr177Asp rs80297119 0.6305 ESP 0.1768 0.1422 2 DM? B|LB Likely benign Likely benign* Benign
MYO7A c.2236G > A p.Asp746Asn rs36090425 0.7388 1000G 0.1877 0.2000 7 DM B Likely benign Benign** Benign
MYO7A c.4805G > A p.Arg1602Gln rs139889944 1.1781 1000G 0.3375 0.3117 30 DM? LB|P Likely benign Benign** Benign
MYO7A c.6614_6634dup p.Met2205_Ser2211dup rs563508617 0.6789 1000G 0.1674 0.1806 2 — — VUS Benign** Benign
GJB2 c.608T > C p.Ile203Thr rs76838169 1.0184 1000G 0.4016 0.3955 31 DM? B Benign Benign** Benign
GJB2 c.35delG p.Gly12ValfsTer2 rs80338939 0.7429 ESP 0.5946 0.5678 10 DM P Pathogenic Pathogenic** Pathogenic
GJB2 c.-15C > T NA rs72561725 1.7530 ESP 0.004777 0.4414 36 DM? B|LB Likely benign VUS** Benign
Table 1. Profiles of variants with observed AF above thresholds and filtering gnomAD AF below thresholds. 
*Corresponding genes were not evaluated by the ClinGen Expert committee; therefore, we applied the modified 
ACMG guidelines suggested by ClinGen Hearing Loss Working Group. **Corresponding genes were evaluated 
by the ClinGen Expert committee but the specific variant was not; therefore, we applied the modified ACMG 
guidelines suggested by ClinGen Hearing Loss Working Group. Red bold letters indicate pathogenic mutations 
concordantly determined by NSHL-optimized ACMG, Expert Specified ACMG by ClinGen, and Deafness 
Variation Database (DVD) classification, even though their observed AFs were above thresholds and their 
filtering AFs were below thresholds.
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Contamination of the gnomAD with pathogenic variants, or HGMD and ClinVar with benign variants is 
another issue that should be considered in the context of NSHL genetic landscape. Only a few NSHL-related 
genes have been selected for report even in newborn genomic sequencing29, probably because some genetic var-
iants linked to NSHL are partly associated with late onset or moderate penetrance with unclear severity, which 
may explain why some pathogenic variants have a relatively high AF in gnomAD. Hereditary hearing loss can be 
further aggravated by such factors as aging and noise exposure30, which might lead to confusion and deposition 
of false-positive data in mutation databases, including HGMD and ClinVar. As the clinical utility of in silico algo-
rithms was shown to be insufficient for variant reclassification31, our study demonstrated that accurate calculation 
of AF thresholds might minimize errors and help avoiding false-negative or false-positive results, especially in the 
identification of benign variants.
Several previous studies have attempted to improve the accuracy in clinical variant interpretation for 
Mendelian disorders by using large databases32–34. In our study, we specifically focused on NSHL, which has a 
very heterogeneous genetic landscape; therefore, comprehensive assessment should be performed to make appro-
priate updates as new information emerges. Our approach, together with other strategies such as AUDIOME10, a 
tiered exome sequencing-based panel, might enhance the clinical utility of NGS and promote the implementation 
of precision medicine in NSHL35.
Our study has several limitations. First, our results were obtained based on the global AF and, thus, may be dif-
ferent from those obtained using other population-specific AFs. Indeed, in the context of clinical genetic testing, 
patient ethnicity should be considered. However, the determination of AF thresholds might require as many allele 
Figure 3. Classification of 1,960 missense variants linked to hearing loss according to in-silico prediction and 
filtering allele frequency. A total of 1,960 missense mutations were evaluated for pathogenicity using the NSHL-
optimized ACMG guidelines and InterVar. Filtering AFs were compared with AF thresholds calculated in this 
study: 0.1% for dominant genes (Dom), and 0.6% for recessive (Rec) and dominant/recessive (Dom/Rec) genes, 
respectively. Relative proportions of pathogenic and benign variants and variants of unknown significance 
(VUS) according to in-silico prediction were shown.
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counts from large populations as possible, and since the pathogenicity of certain variants is not ethnicity-specific, 
we established universal minor allele frequency cutoff values for hearing loss variants. Second, there is an ongoing 
debate about the existence of accurate prevalence and penetrance data. Nevertheless, we think that in our study, 
meaningful calculations of AF thresholds were done based on a statistically robust framework for NSHL variant 
interpretation. As disease-specific thresholds are recommended, we believe that our safe, although seemingly 
lenient, AF thresholds should increase cost-effectiveness in NSHL genetic testing.
In conclusion, we suggest AF thresholds for NSHL-linked gene variants using gnomAD-based filtering AFs 
for precise evaluation of variant pathogenicity in the context of NSHL-optimized ACMG guidelines. This system-
atic approach can be applied to evaluate causality of sequence variants in hearing loss-related genes, which would 
promote accurate diagnosis of hearing loss and development of precision medicine approaches clearly beneficial 
for NSHL patients.
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